National Asset Management, Inc. Aldeyra Therapeutics, Inc. Transaction History

National Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$6.31 - $8.13 $64,677 - $83,332	-10,250 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$4.0 - $7.53 $41,000 - $77,182	10,250 New	10,250 $76,000
Q2 2020 Jul 31, 2020	SELL	$1.97 - $5.05 $43,537 - $111,605	-22,100 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$1.62 - $6.4 $4,860 - $19,200	-3,000 Reduced 11.95%	22,100 $55,000
Q4 2019 Feb 10, 2020	BUY	$4.73 - $7.98 $12,534 - $21,147	2,650 Added 11.8%	25,100 $146,000
Q3 2019 Nov 12, 2019	SELL	$4.41 - $6.12 $17,886 - $24,822	-4,056 Reduced 15.3%	22,450 $119,000
Q2 2019 Aug 05, 2019	SELL	$6.0 - $9.0 $3,000 - $4,500	-500 Reduced 1.85%	26,506 $160,000
Q1 2019 May 08, 2019	BUY	$7.14 - $9.85 $79,011 - $109,000	11,066 Added 69.42%	27,006 $244,000
Q4 2018 Feb 08, 2019	BUY	$7.26 - $13.29 $14,520 - $26,580	2,000 Added 14.35%	15,940 $133,000
Q3 2018 Nov 08, 2018	BUY	$6.8 - $14.35 $94,792 - $200,039	13,940 New	13,940 $193,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.